18FDG PET in lymphoma

Archive of Oncology

关键词: Positron-Emission Tomography and Computed Tomography;    Lymphoma;    Fluorodeoxyglucose F18;    Hodgkin Disease;    Lymphoma;    Non-Hodgkin;   

DOI  :  10.2298/AOO1204094G

来源: DOAJ

【 摘 要 】

18F-FDG PET/CT has become essential in the management of patients withHodgkin’s and non-Hodgkin’s lymphoma. The utility of 18F-FDG PET/CT imagingis based upon increased anaerobic metabolism of neoplastic tissue. The degreeof hypermetabolism is somewhat proportional to lymphoma grade. Based on theability of 18F-FDG PET/CT to identify hypermetabolic tissue, it has greatersensitivity and specificity for the detection of tumors in general andlymphoma in particular compared to CT or MRI. 18FFDG PET/CT has made asignificant impact in lymphoma management in the following instances: 1.Extent of disease in patients already diagnosed with lymphoma; 2.Identification of hypermetabolic disease in lymphadenopathy identified byother means; 3. Evaluation of response to therapy - with greater specificitythan CT alone; 4. Early detection of recurrent disease; 5. Identification oftransformation from low grade to high-grade lymphoma; 6. Prediction ofresponse to therapy and prognosis. In many clinical trials, 18F-FDG PET/CThas replaced CT as the standard for assessment of residual disease. It hasbecome a standard procedure at the time of initial diagnosis and followingcompletion of therapy as well at 6-24 month intervals during the follow-up orupon the recurrence of symptoms suggestive of relapse. On an investigationalbasis, we have demonstrated that resolution of lymph node hypermetabolism, asearly as following a single cycle of chemotherapy, is predictive of aprolonged disease-free interval whereas failure to respond after a singlecycle indicates that even if there is resolution of disease after completionof a full course of treatment, relapse occurs earlier. If confirmed byadditional studies, early 18F-FDG PET/CT evaluation of response may provide abasis to select patients for a change to more aggressive or alternatetherapy. In fact, it may also identify a sub-population of patients who donot require an extended course of chemotherapy.

【 授权许可】

Unknown